Fish oil and mental health: The role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders

International Clinical Psychopharmacology

Volumn 21, Issue 6, 2006, Pages 319-336

  Assisi, Alessandro ^a   Banzi, Rita ^a   Buonocore, Carmela ^a   Capasso, Filippo ^a   Muzio, Valeria Di ^a   Michelacci, Francesca ^a   Renzo, Danila ^a   Tafuri, Giovanni ^a   Trotta, Francesco ^a   Vitocolonna, Maria ^a   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer's disease; Animal model; Attention deficit hyperactive disorder; Cognitive function; Depression; Fish oil; Mental disorder; n 3 long chain polyunsaturated fatty acid; Neurodevelopment; Schizophrenia

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID ETHYL ESTER; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BRAIN FUNCTION; CLINICAL TRIAL; COGNITIVE DEVELOPMENT; DEPRESSION; HUMAN; MENTAL HEALTH; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; PUERPERAL DEPRESSION; REVIEW; SCHIZOPHRENIA; SUPPLEMENTATION; TERM BIRTH;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CHILD DEVELOPMENT; COGNITION; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENTAL DISORDERS; MENTAL HEALTH; MICE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PREGNANCY; RATS;

EID: 33749368592     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224790.98534.11     Document Type: Review

References (185)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, District Columbia: American Psychiatric Association.
3. Anderson JW, Johnstone BM, Remley DT (1999). Breast-feeding and cognitive development: a meta-analysis. Am J Clin Nutr 70:525-535.
4. Anderson GJ, Neuringer M, Lin DS, Connor WE (2005). Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr Res 58:865-872.
5. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP (2003a). Supplementation with a combination of (omega)-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62:195-204.
6. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, et al. (2003b). Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53:56-64.
7. Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH (2001). Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 49:510-522.
8. Auestad N, Halter R, Hall RT, Blatter M, Bogle ML, Burks W, et al. (2001). Growth and development in term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study. Pediatrics 108:372-381.
9. Bakker EC, Ghys AJ, Kester AD, Vles JS, Dubas JS, Blanco CE, et al. (2003). Long-chain polyunsaturated fatty acids at birth and cognitive function at 7 y of age. Eur J Clin Nutr 57:89-95.
10. Barcelo-Coblijn G, Kitajka K, Puskas LG, Hogyes E, Zvara A, Hackler L Jr, et al. (2003). Gene expression and molecular composition of phospholipids in rat brain in relation to dietary n-6 to n-3 fatty acid ratio. Biochim Biophys Acta 1632:72-79.
11. Berger-Sweeney J, Arnold A, Gabeau D, Mills J (1995). Sex differences in learning and memory in mice: effects of sequence of testing and cholinergic blockade. Behav Neurosci 109:859-873.
12. Berk RA (1979). The discriminative efficiency of the Bayley Scales of Infant Development. J Abnorm Child Psychol 7:113-119.
13. Bjerve KS (1991). Omega 3 fatty acid deficiency in man: implications for the requirement of alpha-linolenic acid and long-chain omega 3 fatty acids. World Rev Nutr Diet 66:133-142.
14. Boston PF, Bennett A, Horrobin DF, Bennett CN (2004). Ethyl-EPA in Alzheimer's disease: a pilot study. Prostaglandins Leukot Essent Fatty Acids 71:341-346.
15. Burgess JR, Stevens L, Zhang W, Peck L (2000). Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 71:327S-330S.
16. Burr G, Burr M (1929). A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 82:345-367.
17. Calder PC, Grimble RF (2002). Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 56(Suppl 3):S14-S19.
18. Caldwell DF, Churchill JA (1966). Learning impairment in rats administered a lipid free diet during pregnancy. Psychol Rep 19:99-102.
19. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, et al. (2004). Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633-645.
20. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, et al. (2005). Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 22:617-626.
21. Carlson SE, Cooke RJ, Werkman SH, et al. (1992). First year growth of preterm infants fed standard compared to marine oil n-3 supplemented formula. Lipids 27:901-907.
22. Carlson SE, Cooke RJ, Werkman SH, Tolley EA (1996). Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. Am J Clin Nutr 63:687-697.
23. Carrie I, Clement M, De Javel D, Frances H, Bourre JM (1999). Learning deficits in first generation OF1 mice deficient in (n-3) polyunsaturated fatty acids do not result from visual alteration. Neurosci Lett 266:69-72.
24. Carrie I, Guesnet P, Bourre JM, Frances H (2000a). Diets containing long-chain n-3 polyunsaturated fatty acids affect behaviour differently during development than ageing in mice. Br J Nutr 83:439-447.
25. Carrie J, Clement M, De Javel D, Frances H, Bourre J-M (2000b). Phospholipid supplementation reverses behavioral and biochemical alterations induced by n-3 polyunsaturated fatty acid deficiency in mice. J Lipid Res 41:473-480.
26. Catalan J, Moriguchi T, Slotnick B, Murthy M, Greiner RS, Salem N Jr. (2002). Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci 116:1022-1031.
27. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet A-M, Besnard J-C, et al. (1998). Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 128:2512-2519.
28. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G (2001). Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 36:937-944.
29. Chen C, Tonegawa S (1997). Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Annu Rev Neurosci 20:157-184.
30. Chen J-R, Hsu S-F, Hsu C-D, Hwang L-H, Yang S-C (2004). Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem 15:467-472.
31. Chiu CC, Huang SY, Shen WW, Su KP (2003a). Omega-3 fatty acids for depression in pregnancy. Am J Psychiatry 160:385.
32. Chiu CC, Huang SY, Su KP, Lu ML, Huang MC, Chen CC, et al. (2003b). Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol 13:99-103.
33. Christensen O, Christensen E (1988). Fat consumption and schizophrenia. Acta Psychiatr Scand 78:587-591.
34. Clandinin MT, Van Aerde JE, Merkel KL, Harris CL, Springer MA, Hansen JW, et al. (2005). Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. J Pediatr 146:461-468.
35. Clements KM, Girard TA, Xing H-C, Wainwright PE (2003). Spontaneously hypertensive and Wistar Kyoto rats differ in delayed matching-to-place performance and response to dietary long-chain polyunsaturated fatty acids. Dev Psychobiol 43:57-69.
36. Colombo J, Kannass KN, Shaddy DJ, Kundurthi S, Maikranz JM, Anderson CJ, et al. (2004). Maternal DHA and the development of attention in infancy and toddlerhood. Child Dev 75:1254-1267.
37. Connor WE, Neuringer M, Reisbick S (1992). Essential fatty acids: the importance of n-3 fatty acids in the retina and brain. Nutr Rev 50:21-29.
38. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH (2000). Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35:1305-1312.
39. Cott J, Hibbeln JR (2001). Lack of seasonal mood change in Icelanders. Am J Psychiatry 158:328.
40. Das UN (2003). Long-chain polyunsaturated fatty acids in the growth and development of the brain and memory. Nutrition 19:62-65.
41. De Ferrari GV, Inestrosa NC (2000). Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev 33:1-12.
42. De Vriese SR, Christophe AB, Maes M (2003). Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci 73:3181-3187.
43. Delion SS, Chalon S, Herault J, Guilloteau D, Besnard J-C, Durand G (1994). Chronic dietary alpha-linolenic acid deficiency alters dopamine and seratoninergic neurotrasmission in rats. J Nutr 124:2466-2476.
44. du Bois TM, Deng C, Huang XF (2005). Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:878-888.
45. Edwards R, Peet M, Shay J, Horrobin D (1998). Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 48:149-155.
46. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ (2002). Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159:1596-1598.
47. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC, et al. (2002). Diet and risk of dementia: does fat matter? The Rotterdam Study. Neurology 59:1915-1921.
48. Enslen M, Milon H, Malnoe A (1991). Effect of low intake of n-3 fatty acids during development on brain phospholipid fatty acid composition and exploratory behavior in rats. Lipids 26:203-208.
49. Farkas T, Kitajka K, Fodor E, Csengeri I, Lahdes E, Yeo YK, et al. (2000). Docosahexaenoic acid-containing phospholipid molecular species in brains of vertebrates. Proc Natl Acad Sci USA 97:6362-6366.
50. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M (2001). A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158:2071-2074.
51. Frances H, Monier C, Bourre JM (1995). Effects of dietary alpha-linolenic acid deficiency on neuromuscular and cognitive functions in mice. Life Sci 57:1935-1947.
52. Frances H, Coudereau JP, Sandouk P, Clement M, Monier C, Bourre JM (1996). Influence of a dietary alpha-linolenic acid deficiency on learning in the Morris water maze and on the effects of morphine. Eur J Pharmacol 298:217-225.
53. Friedland R (2003). Fish consumption and the risk of Alzheimer disease: is it time to make dietary recommendations? Arch Neurol 60:923-924.
54. Fujimoto K (1989.) The effect of dietary docosahexaenoate on the learning ability of rats. In: Chandra RK, editor. Health effects of fish and fish oils. The Netherlands: ARTS Biomedical Publishers & Distributors. pp. 275-284.
55. Gamoh S, Hashimoto M, Sugioka K, Shahdat Hossain M, Hata N, Misawa Y, et al. (1999). Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93:237-241.
56. Gamoh S, Hashimoto M, Hossain S, Masumura S (2001). Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 28:266-270.
57. Gibson EL, Barnfield AM, Curzon G (1994). Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects. Neuropharmacology 33:457-465.
58. Gibson RA, Neumann MA, Makrides M (1997). Effect of increasing breast milk docosahexaenoic acid on plasma and erythrocyte phospholipid fatty acids and neural indices of exclusively breast fed infants. Eur J Clin Nutr 51:578-584.
59. Greenberg LM, Waldman ID (1993). Developmental normative data on the test of variables of attention (T.O.V.A.). J Child Psychol Psychiatry 34:1019-1030.
60. Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lonnqvist J (2004). Is low dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry 161:567-569.
61. Hamazaki T, Sawazaki S, Itomura M, Asaoka E, Nagao Y, Nishimura N, et al. (1996). The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest 97:1129-1133.
62. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, et al. (2002). Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81:1084-1091.
63. Helland IB, Saugstad OD, Smith L, Saarem K, Solvoll K, Ganes T, et al. (2001). Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics 108:E82.
64. Hendley ED (2000). WKHA rats with genetic hyperactivity and hyperreactivity to stress: a review. Neurosci Biobehav Rev 24:41-44.
65. Heude B, Ducimetiere P, Berr C (2003). Cognitive decline and fatty acid composition of erythrocyte membranes-The EVA Study. Am J Clin Nutr 77:803-808.
66. Hibbeln J (2002). Seafood consumption, the DHA content of mother's milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affective Disord 69:15-29.
67. Hibbeln JR (1998). Fish consumption and major depression. Lancet 1998 Apr 18; 351:1213%N 9110.
68. Hirashima F, Parow AM, Stoll AL, Demopulos CM, Damico KE, Rohan ML, et al. (2004). Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry 161:1922-1924.
69. Hogyes E, Nyakas C, Kiliaan A, Farkas T, Penke B, Luiten PG (2003). Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 119:999-1012.
70. Holman R, Johnson S, TF H (1982). A case of human linolenic acid deficiency involving neurological abnormalities. Am J Clin Nutr 35:617-623.
71. Horrobin DF (1977). Schizophrenia as a prostaglandin deficiency disease. Lancet I:936-937.
72. Horrobin DF (1998). The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30:193-208.
73. Horrobin DF, Glen AIM, Vaddadi K (1994). The membrane hypothesis of schizophrenia. Schizophr Res 13:195-207.
74. Horrocks LA, Farooqui AA (2004). Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 70:361-372.
75. Hossain MS, Hashimoto M, Gamoh S, Masumura S (1999). Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. J Neurochem 72:1133-1138.
76. Hoza B, Vallano G, Pelham WE (1995). Attention-deficit hyperactivity disorder. In: Handbook of child behavior therapy in the psychiatric setting. Ammerman RT, Hersen M, editors. New York: Wiley.
77. Hudson CJ, Kennedy JL, Gotowiec A, Lin A, King N, Gojtan K, et al. (1996). Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr Res 21:111-116.
78. Hulbert AJ, Turner N, Storlien LH, Else PL (2005). Dietary fats and membrane function: implications for metabolism and disease. Biol Rev Camb Philos Soc 80:155-169.
79. Ikemoto A, Ohishi M, Sato Y, Hata N, Misawa Y, Fujii Y, et al. (2001). Reversibility of n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: level of n-6 fatty acids as another critical factor. J Lipid Res 42:1655-1663.
80. Innis S (2005). Essential fatty acid transfer and fetal development. Placenta 26:S70-S75.
81. Issemann I, Prince RA, Tugwood JD, Green S (1993). The peroxisome proliferator-activated receptor: retinoid x receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 11:37-47.
82. Itoh A, Nitta A, Nadai M, Nishimura K, Hirose M, Hasegawa T, et al. (1996). Dysfunction of cholinergic and dopaminergic neuronal systems in betaamyloid protein-infused rats. J Neurochem 66:1113-1117.
83. Itoh A, Akaike T, Sokabe M, Nitta A, Iida R, Olariu A, et al. (1999). Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. Eur J Pharmacol 382:167-175.
84. James MJ, Gibson RA, Cleland LG (2000). Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71:343S-348S.
85. Jensen MM, Skarsfeldt T, Hoy CE (1996). Correlation between level of (n-3) polyunsaturated fatty acids in brain phospholipids and learning ability in rats. A multiple generation study. Biochim Biophys Acta 1300:203-209.
86. Jensen CL, Voigt RG, Prager TC, Zou YL, Fraley JK, Rozelle JC, et al. (2005). Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants. Am J Clin Nutr 82:125-132.
87. Joy CB, Mumby-Croft R, Joy LA (2003). Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev CD001257, Vol. 2.
88. Jump DB (2002). Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 13:155-164.
89. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D (1997a). Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 145:33-41.
90. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM (1997b). Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42:776-782.
91. Kalmijn S, Van Boxtel MPJ, Ocke M, Verschuren WMM, Kromhout D, Launer LJ (2004). Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 62:275-280.
92. Keshavan MS, Stanley JA, Pettegrew JW (2000). Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings - part II. Biol Psychiatry 48:369-380.
93. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (2002). Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58:1-10.
94. Kitajka K, Puskas LG, Zvara A, Hackler L Jr, Barcelo-Coblijn G, Yeo YK, et al. (2002). The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci USA 99:2619-2624.
95. Kyle DJ, Schaefer E, Patton G, Beiser A (1999). Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 34 (Suppl):S245.
96. Lauritzen L, Hoppe C, Straarup EM, Michaelsen KF (2005). Maternal fish oil supplementation in lactation and growth during the first 2.5 years of life. Pediatr Res 58:235-242.
97. Lewin GA, Schachter HM, Yuen D, Merchant P, Mamaladze V, Tsertsvadze A (2005). Effects of omega-3 fatty acids on child and maternal health. Evid Rep Technol Assess (Summer) 2005 Aug:(118):1-11.
98. Lim SY, Suzuki H (2000). Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr 130:1629-1632.
99. Lim SY, Suzuki H (2001). Changes in maze behavior of mice occur after sufficient accumulation of docosahexaenoic acid in brain. J Nutr 131:319-324.
100. Lim WS, Gammack J, Van Niekerk J, Dangour A (2005). Omega-3 fatty acids for the prevention of dementia (protocol). Cochrane Database Syst Rev: CD005379 3:1-8.
101. Llorente AM, Jensen CL, Voigt RG, Fraley JK, Berretta MC, Heird WC (2003). Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol 188:1348-1353.
102. Logan A (2004). Omega-3 fatty acids and major depression: a primer for mental health professional. Lipids Health Dis 3:25.
103. Lucas A, Morley R, Cole TJ (1998). Randomised trial of early diet in preterm babies and later intelligence quotient. BMJ 317:1481-1487.
104. Lucas A, Stafford M, Morley R, Abbott R, Stephenson T, MacFadyen U, et al. (1999). Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomised trial. Lancet 354:1948-1954.
105. Maes M, Smith RS (1998). Fatty acids, cytokines, and major depression. Biol Psychiatry 43:313-314.
106. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H (1996). Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 38:35-46.
107. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999). Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 85:275-291.
108. Mahadik SP, Evans DR (2003). Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 26:85-102.
109. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE (1996). Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 63:133-142.
110. Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA (1994). Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr 60:189-194.
111. Malnoe A, Milon H, Reme C (1990). Effect of in vivo modulation of membrane docosahexaenoic acid levels on the dopamine-dependent adenylate cyclase activity in the rat retina. J Neurochem 55:1480-1485.1
112. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HFS, Puryear LJ (2003). A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160:996-998.
113. Marangell LB, Martinez JM, Zboyan HA, Chong H, Puryear LJ (2004). Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. Depress Anxiety 19:20-23.
114. Martin RE, Bazan NG (1992). Changing fatty acid content of growth cone lipids prior to synaptogenesis. J Neurochem 59:318-325.
115. McCann JC, Ames BN (2005). Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 82:281-295.
116. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, et al. (1997). Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 58:1123-1129.
117. Montine TJ, Morrow JD (2005). Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol 166:1283-1289.
118. Moriguchi T, Salem N Jr. (2003). Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J Neurochem 87:297-309.
119. Moriguchi T, Loewke J, Garrison M, Catalan JN, Salem N Jr. (2001). Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. J Lipid Res 42:419-427.
120. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. (2003). Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60:940-946.
121. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. (1995). Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332:1198-1203.
122. Nakashima Y, Yuasa S, Hukamizu Y, Okuyama H, Ohhara T, Kameyama T, et al. (1993). Effect of a high linoleate and a high alpha-linolenate diet on general behavior and drug sensitivity in mice. J Lipid Res 34:239-247.
123. Nemets B, Stahl Z, Belmaker RH (2002). Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159:477-479.
124. Neuringer M, Connor WE (1986). n-3 fatty acids in the brain and retina: evidence for their essentiality. Nutr Rev 44:285-294.
125. Nitta A, Itoh A, Hasegawa T, Nabeshima T (1994). beta-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 170:63-66.
126. Nitta A, Fukuta T, Hasegawa T, Nabeshima T (1997). Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 73:51-57.
127. O'Connor DL, Hall R, Adamkin D, Auestad N, Castillo M, Connor WE, et al. (2001). Growth and development in preterm infants fed long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial. Pediatrics 108:359-371.
128. O'Connor DL, Jacobs J, Hall R, Adamkin D, Auestad N, Castillo M, et al. (2003). Growth and development of premature infants fed predominantly human milk, predominantly premature infant formula, or a combination of human milk and premature formula. J Pediatr Gastroenterol Nutr 37:437-446.
129. Otto SJ, de Groot RH, Hornstra G (2003). Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status. Prostaglandins Leukot Essent Fatty Acids 69:237-243.
130. Pary R, Lewis S, Matuschka PR, Lippmann S (2002). Attention-deficit/ hyperactivity disorder: an update. South Med J 95:743-749.
131. Peet M, Horrobin DF (2002a). A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 36:7-18.
132. Peet M, Horrobin DF (2002b). A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59:913-919.
133. Peet M, Laugharne JD, Mellor J, Ramchand CN (1996). Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 55:71-75.
134. Peet M, Murphy B, Shay J, Horrobin D (1998). Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 43:315-319.
135. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK (2001). Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49:243-251.
136. Poling JS, Karanian JW, Salem N Jr, Vicini S (1995). Time- and voltage-dependent block of delayed rectifier potassium channels by docosahexaenoic acid. Mol Pharmacol 47:381-390.
137. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001). Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21:4183-4187.
138. Puri BK, Steiner R (1998). Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid (multiple letters). Arch Gen Psychiatry 55:188-189.
139. Puri BK, Cousell SJ, Hamilton G, Richardson AJ, Horrobin DF (2001). Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract 55:560-563.
140. Puskas LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farkas T (2003). Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci USA 100:1580-1585.
141. Rafalowska U, Liu G, Floyd R (1989). Peroxidation induced changes in synaptosomal transport of dopamine and gammaaminobutyric acid. Free Radic Biol Med 6:485-492.
142. Richardson AJ, Montgomery P (2005). The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 115:1360-1366.
143. Richardson AJ, Puri BK (2002). A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progr Neuro-Psychopharmacol Biol Psychiatry 26:233-239.
144. Richardson AJ, Easton T, Puri BK (2000). Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Eur Neuropsychopharmacol 10:189-193.
145. Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldassano CF, Yildiz A (2005). Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J 4:6.
146. Salem N (1989). Omega-3 fatty acids: molecular and biochemical aspects. In: New protective role for selected nutrients. Spilier G, Scala J, editors. New York: Alan R. Liss, Inc.; pp. 109-228.
147. Schachar R, Tannock R, Cunningham C (1996.) Hyperactivity disorders of childhood. Cambridge, England: Cambridge University Press.
148. Schmidt AJ, Krieg JC, Vedder H (2005). Antioxidative and steroid systems in neurological and psychiatric disorders. World J Biol Psychiatry 6:26-35.
149. Schwartz R, Skolnick P, Paul S (1988). Regulation of gamma-aminobutyric acid/barbiturate receptor gated chloride ion flux in brain vesicles by phospholipase A2: possible role of oxygen radicals. J Neurochem 50:565-571.
150. Seo T, Blaner WS, Deckelbaum RJ (2005). Omega-3 fatty acids: molecular approaches to optimal biological outcomes. Curr Opin Lipidol 16:11-18.
151. Shaldubina A, Nemets B, Bersudsky Y (2002). Lack of effect of eicosapentaenoic acid in the Porsolt forced swimming test model of depression. Acta Neuropsychiatr 14:203-206.
152. Silvers KM, Woolley CC, Hamilton FC, Watts PM, Watson RA (2005). Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 72:211-218.
153. Simmer K (2001). Longchain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 2001; (4): CD000376.
154. Simmer K, Patole S (2004). Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 2004; (1): CD000375.
155. Slater SJ, Kelly MB, Yeager MD, Larkin J, Ho C, Stubbs CD (1996). Polyunsaturation in cell membranes and lipid bilayers and its effects on membrane proteins. Lipids 31 (Suppl):S189-S192.
156. Smuts CM, Borod E, Peeples JM, Carlson SE (2003). High-DHA eggs: Feasibility as a means to enhance circulating DHA in mother and infant. Lipids 38:407-414.
157. Songur A, Sarsilmaz M, Sogut S, Ozyurt B, Ozyurt H, Zararsiz I, et al. (2004). Hypothalamic superoxide dismutase, xanthine oxidase, nitric oxide, and malondialdehyde in rats fed with fish (omega)-3 fatty acids. Prog NeuroPsychopharmacol Biol Psychiatry 28:693-698.
158. Spencer T, Biederman J, Wilens TE, Faraone SV (1994). Is attention deficit hyperactivity disorder in adults a valid disorder? Harv Rev Psychiatry 1994 Mar-Apr; 1(6):326-335.
159. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, et al. (1995). Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 62:761-768.
160. Stoll AL, Locke CA, Marangell LB, Severus WE (1999a). Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids 60:329-337.
161. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. (1999b). Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56:407-412.
162. Su KP, Huang SY, Chiu CC, Shen WW (2003). Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13:267-271.
163. Swanson J, Castellanos FX, Murias M, LaHoste G, Kennedy J (1998). Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol 8:263-271.
164. Takeuchi T, Iwanaga M, Harada E (2003). Possible regulatory mechanism of DHA-induced anti-stress reaction in rats. Brain Res 964:136-143.
165. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, et al. (2003). Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89:483-489.
166. Turner N, Else PL, Hulbert AJ (2003). Docosahexaenoic acid (DHA) content of membranes determines molecular activity of the sodium pump: implications for disease states and metabolism. Naturwissenschaften 90:521-523.
167. Umezawa M, Ohta A, Tojo H, Yagi H, Hosokawa M, Takeda T (1995). Dietary
168. Villarroel A, Schwarz TL (1996). Inhibition of the Kv4 (Shal) family of transient K + currents by arachidonic acid. J Neurosci 16:1016-1025.
169. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC (2001). A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 139:189-196.
170. Wainwright PE (1992). Do essential fatty acids play a role in brain and behavioral development? Neurosci Biobehav Rev 16:193-205.
171. Wainwright PE, Xing HC, Mutsaers L, McCutcheon D, Kyle D (1997). Arachidonic acid offsets the effects on mouse brain and behavior of a diet with a low (n-6): (n-3) ratio and very high levels of docosahexaenoic acid. J Nutr 127:184-193.
172. Williams J, Rickert V, Hogan J, Zolten AJ, Satz P, D'Elia LF, et al. (1995). Children's color trails. Arch Clin Neuropsychol 10:211-223.
173. Wu D, Meydani SN (1998). n-3 polyunsaturated fatty acids and immune function. Proc Nutr Soc 57:503-509.
174. Xiao Y, Li X (1999). Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 846:112-121.
175. Yacubian J, de Castro CC, Ometto M, Barbosa E, de Camargo CP, Tavares H, et al. (2002). 31P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism. Schizophr Res 58:117-122.
176. Yamamoto N, Saitoh M, Moriuchi A, Nomura M, Okuyama H (1987). Effect of dietary alpha-linolenate/linoleate balance on brain lipid compositions and learning ability of rats ? J Lipid Res 28:144-151.
177. Yamamoto N, Hashimoto A, Takemoto Y, Okuyama H, Nomura M, Kitajima R, et al. (1988). Effect of the dietary alpha-linolenate/linoleate balance on lipid compositions and learning ability of rats. II. Discrimination process, extinction process, and glycolipid compositions. J Lipid Res 29:1013-1021.
178. Yao J, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW (2002). Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry 52:823-830.
179. Yao JK, van Kammen DP, Gurklis JA (1996). Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatry Res 60:11-21.
180. Yehuda S (2003). Omega-6/omega-3 ratio and brain-related functions. In: Omega-6/omega-3 essential fatty acid ratio: the scientific evidence. Simopoulos A, Cleland L, editors. Vol. 92. World Rev Nutr 3 Diet. Basel, Karger: pp. 37-56.
181. Yehuda S, Rabinovitz S, Mostofsky DI (1999a). Essential fatty acids are mediators of brain biochemistry and cognitive functions? J Neurosci Res 56:565-570.
182. Yehuda S, Rabinovitz S, Mostofsky DI (1999b). Treatment with a polyunsaturated fatty acid prevents deleterious effects of Ro4-1284. Eur J Pharmacol 365:27-34.
183. Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI (2002). The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23:843-853.
184. Young GS, Maharaj NJ, Conquer JA (2004). Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 39:117-123.
185. Zimmer L, Hembert S, Durand G, Breton P, Guilloteau D, Besnard JC, et al. (1998). Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci Lett 240:177-181.